Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

227.04 +1.91 (+0.85%)
Streaming Delayed Price Updated: 2:22 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Dividend stocks can be a more predictable stream of income for investors. 
Via The Motley Fool
Topics ETFs Stocks
Here's How Much $100 Invested In AbbVie 5 Years Ago Would Be Worth Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 6.25% on an annualized basis producing an average annual return of 20.98%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
1 Top ETF I Wouldn't Hesitate to Invest $1,000 Into Right Now
This fund makes it easy to invest in the top dividend stocks. 
Via The Motley Fool
Topics ETFs Stocks
How Do Investors Really Feel About AbbVie?
 
Via Benzinga
Why the Schwab U.S. Dividend Equity ETF Could Be a Top Choice for Dividend Investors in 2025
Instead of choosing just one or two stocks, buy a bunch of quality dividend-payers with a single ETF. 
Via The Motley Fool
Topics ETFs Stocks
5 Dividend Powerhouses to Buy and Never Sell
These blue-chip giants have paid shareholders through wars, recessions, and pandemics. 
Via The Motley Fool
Topics Intellectual Property
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital... 
Via MarketMinute
Topics Artificial Intelligence
NEXGEL Inc. Equity Warrants: A High-Stakes Bet on Future Profitability Amidst Rapid Growth
Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW).... 
Via MarketMinute
Topics Intellectual Property
Decoding AbbVie's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE: ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available options... 
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
3 Top Dividend Stocks to Buy and Hold Forever
These blue chip dividend stocks offer both income and growth potential. 
Via The Motley Fool
Topics Intellectual Property
Where Will AbbVie Be in 5 Years?
This big pharmaceutical company should be significantly bigger five years from now. 
Via The Motley Fool
Topics Earnings Economy Government
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program. 
Via Benzinga
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
1 Top Dividend Stock to Buy and Hold Forever
The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run. 
Via The Motley Fool
Topics Economy Initial Public Offering Intellectual Property
Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts
The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In... 
Via MarketMinute
Topics Bonds ETFs Economy
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
There aren't many companies in the industry that offer an excellent combination of growth and income. 
Via The Motley Fool
Topics Intellectual Property
Forever Dividend Stocks: 3 Income Stocks I Never Plan to Sell
Never say never? Maybe not with these great dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Everything is going great for the stock market right now. But a plot twist could be on the way. 
Via The Motley Fool
Topics Economy
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker
Shares skyrocketed after the company said its drug has a half-life of about 100 days. 
Via Investor's Business Daily
This Workday Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in September
The attraction of these dividend stocks isn't limited to their dividends. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.